Honkamp Krueger Financial Services Inc. Sells 431 Shares of Allergan plc (AGN)

Honkamp Krueger Financial Services Inc. lessened its stake in Allergan plc (NYSE:AGN) by 8.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,425 shares of the company’s stock after selling 431 shares during the period. Honkamp Krueger Financial Services Inc.’s holdings in Allergan were worth $724,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in AGN. Itau Unibanco Holding S.A. raised its position in Allergan by 108.4% during the 4th quarter. Itau Unibanco Holding S.A. now owns 1,694 shares of the company’s stock valued at $277,000 after purchasing an additional 881 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Allergan by 479.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,768 shares of the company’s stock valued at $289,000 after purchasing an additional 1,463 shares during the last quarter. UBS Asset Management Americas Inc. raised its position in Allergan by 13.6% during the 4th quarter. UBS Asset Management Americas Inc. now owns 1,763,209 shares of the company’s stock valued at $288,426,000 after purchasing an additional 210,962 shares during the last quarter. Rhumbline Advisers raised its position in Allergan by 2.6% during the 4th quarter. Rhumbline Advisers now owns 534,738 shares of the company’s stock valued at $87,472,000 after purchasing an additional 13,462 shares during the last quarter. Finally, Levin Capital Strategies L.P. raised its position in Allergan by 44.9% during the 4th quarter. Levin Capital Strategies L.P. now owns 654,173 shares of the company’s stock valued at $107,010,000 after purchasing an additional 202,643 shares during the last quarter. 79.66% of the stock is owned by institutional investors.

Allergan plc (NYSE AGN) opened at $164.04 on Tuesday. Allergan plc has a 52-week low of $156.00 and a 52-week high of $256.80. The stock has a market capitalization of $54,185.75, a P/E ratio of -12.22, a PEG ratio of 1.16 and a beta of 1.19. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.04 and a quick ratio of 1.88.

Allergan (NYSE:AGN) last announced its earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.74 by $0.12. The firm had revenue of $4.33 billion during the quarter, compared to analyst estimates of $4.28 billion. Allergan had a positive return on equity of 8.28% and a negative net margin of 26.32%. The business’s revenue was up 12.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.90 EPS. research analysts expect that Allergan plc will post 15.57 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Tuesday, February 27th. This represents a $2.88 annualized dividend and a dividend yield of 1.76%. This is an increase from Allergan’s previous quarterly dividend of $0.70. Allergan’s dividend payout ratio is presently -20.86%.

A number of research analysts have commented on the company. Leerink Swann upped their price target on Allergan from $237.00 to $242.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. Royal Bank of Canada set a $250.00 price target on Allergan and gave the company a “buy” rating in a research report on Sunday, October 29th. They noted that the move was a valuation call. Vetr lowered Allergan from a “buy” rating to a “hold” rating and set a $180.97 price target for the company. in a research report on Wednesday, January 10th. Wells Fargo & Co reaffirmed an “outperform” rating and set a $245.00 price target (down previously from $258.00) on shares of Allergan in a research report on Thursday, November 2nd. Finally, Argus lowered Allergan from a “buy” rating to a “hold” rating and lowered their price target for the company from $256.80 to $160.07 in a research report on Thursday, December 7th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $227.23.

In related news, Director Chris W. Bodine purchased 3,030 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The shares were bought at an average price of $164.77 per share, for a total transaction of $499,253.10. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider William Meury sold 11,807 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $173.89, for a total value of $2,053,119.23. The disclosure for this sale can be found here. Insiders purchased a total of 17,630 shares of company stock worth $2,890,057 in the last 90 days. 0.36% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This article was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/20/honkamp-krueger-financial-services-inc-sells-431-shares-of-allergan-plc-agn.html.

About Allergan

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply